tolbutamide has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Appel, S; Hitzenberger, G; Kalafsky, G; Kallay, Z; Kutz, K; Rüfenacht, T; Tetzloff, W | 1 |
Andersson, TB; Bredberg, E; Ericsson, H; Sjöberg, H | 1 |
Hsiong, CH; Hu, OY; Lee, MS; Pao, LH; Shih, TY; Wang, HJ | 1 |
2 trial(s) available for tolbutamide and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Anticholesteremic Agents; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Glyburide; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Lovastatin; Placebos; Simvastatin; Tolbutamide | 1995 |
An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP2C9; Diclofenac; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Ibuprofen; In Vitro Techniques; Indoles; Male; Mass Spectrometry; Microsomes, Liver; Middle Aged; Tolbutamide | 2004 |
1 other study(ies) available for tolbutamide and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
Article | Year |
---|---|
Dietary flavonoids modulate CYP2C to improve drug oral bioavailability and their qualitative/quantitative structure-activity relationship.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diet; Disaccharides; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Flavonoids; Fluvastatin; Indoles; Male; Microsomes, Liver; Quantitative Structure-Activity Relationship; Quercetin; Rats; Rats, Wistar; Tolbutamide | 2014 |